FDA Pushes the Last DSCSA Deadline to November 2027
Small dispensers and, where applicable, their trading partners get another year of exemption while the agency finishes its assessment of what full serialisation would cost them.
The US Food and Drug Administration has extended its exemptions from certain requirements of section 582 of the Federal Food, Drug, and Cosmetic Act for small dispensers — pharmacies, in practice — and, where applicable, their trading partners, until 27 November 2027. That moves the date on from 27 November 2026, which had itself been set in an exemption letter dated 12 July 2024.
The definition of small is specific. A dispenser qualifies if, as of 27 November 2026, the corporate entity that owns it has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians under state board of pharmacy rules. That is a headcount test on a fixed date, not a rolling one, and it is worth reading carefully by anyone close to the boundary.
The stated reason for the extension is procedural rather than substantive: the agency wants time to finish its small dispensers assessment, publish a final assessment report for public comment, and hold a public meeting on it. FDA encourages small dispensers to complete the assessment survey by 22 September 2026, and consultants or other designated entities may complete it on their behalf.
The administrative detail matters for anyone building systems around this. Trading partners using the exemption need submit nothing to FDA. Those who do not qualify must request a waiver, exception or exemption through CDER NextGen for CDER products, or through the Electronic Submissions Gateway or the CBER waiver mailbox for CBER products.
The engineering reading is that the interoperable, electronic, package-level traceability the act requires has not gone away — the largest trading partners have been operating under it since late 2024, and the data those systems exchange is unchanged. What has moved is the point at which the smallest participants must be able to receive and use it. Anyone building or integrating a pharmacy system now has a longer runway to the same destination, and one more year in which their partners' data will arrive in formats their own software may not yet read.
Source: US Food and Drug Administration